Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026)
Quarterly Share-based Compensation rose 118.32% to $6.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $23.0 million through Mar 2026, up 80.81% year-over-year, with the annual reading at $20.1 million for FY2025, 79.77% up from the prior year.
Oculis Holding AG's Share-based Compensation history spans 5 years, with the latest figure at $6.4 million for Q1 2026.
- Share-based Compensation came in at $6.4 million for Q1 2026, up from $5.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $6.4 million in Q1 2026 to a low of $150513.2 in Q4 2022.
- The 5-year median for Share-based Compensation is $2.9 million (2024), against an average of $2.8 million.
- Year-over-year, Share-based Compensation surged 733.86% in 2024 and then soared 50.32% in 2025.
- Oculis Holding AG's Share-based Compensation stood at $150513.2 in 2022, then surged by 680.47% to $1.2 million in 2023, then soared by 176.17% to $3.2 million in 2024, then skyrocketed by 66.3% to $5.4 million in 2025, then rose by 18.37% to $6.4 million in 2026.
- Per Business Quant, the three most recent readings for OCS's Share-based Compensation are $6.4 million (Q1 2026), $5.4 million (Q4 2025), and $5.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 257.40 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | 6.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.39 Mn |
| Mar 31, 2026 | 6.39 Mn |
| Dec 31, 2025 | 5.40 Mn |
| Dec 31, 2025 | 5.40 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 3.65 Mn |
| Jun 30, 2024 | 3.65 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 156,768.57 |
| Mar 31, 2023 | 156,768.57 |
| Dec 31, 2022 | 150,513.18 |
| Dec 31, 2022 | 150,513.18 |
| Sep 30, 2022 | 200,878.59 |
| Sep 30, 2022 | 200,878.59 |